MannKind (MNKD)
(Delayed Data from NSDQ)
$6.60 USD
-0.10 (-1.49%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MNKD 6.60 -0.10(-1.49%)
Will MNKD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MNKD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNKD
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?
MannKind (MNKD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
MNKD: What are Zacks experts saying now?
Zacks Private Portfolio Services
MannKind (MNKD) Q2 Earnings and Revenues Surpass Estimates
All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy
Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?
Other News for MNKD
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MannKind receives clearance in Japan to begin Phase 3 study on Clofazimine
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 25,000 Shares of MannKind ...
Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 80,000 Shares of MannKind ...